Details of the Drug Combinations

General Information of This Drug (ID: DM0L6E1)

Drug Name

Cycloleucine DM0L6E1

Synonyms

cycloleucine; 1-Aminocyclopentanecarboxylic acid; 52-52-8; 1-Aminocyclopentane-1-carboxylic acid; Cycloleucin; 1-Amino-1-cyclopentanecarboxylic acid; 1-Amino-1-carboxycyclopentane; 1-Amino-cyclopentanecarboxylic acid; CYCLO-LEUCINE; Cyclopentanecarboxylic acid, 1-amino-; NSC 1026; CB 1639; X 201; UNII-0TQU7668EI; 1-Aminocyclopentanecarboxylate; HSDB 5195; WR 14,997; NSC1026; 1-amino cyclopentane carboxylic acid; EINECS 200-144-6; BRN 0636626; aminocyclopentanecarboxylic acid; Cyclopentanecarboxylic acid, 1-amino-, L-; AI3-26442

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

4 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Cycloleucine + Irinotecan	DC2O9OY	Irinotecan	Esophageal Cancer	[2]
Cycloleucine + Paclitaxel	DC8G0PS	Paclitaxel	Esophageal Cancer	[2]
Cycloleucine + Etoposide	DCL0ZQE	Etoposide	Extensive Stage Small Cell Lung Cancer	[3]
Cycloleucine + Etoposide	DCPSSFJ	Etoposide	Extensive Stage Small Cell Lung Cancer	[3]
------------------------------------------------------------------------------------

References

1	Effects of D-cycloserine and cycloleucine, ligands for the NMDA-associated strychnine-insensitive glycine site, on brain-stimulation reward and spontaneous locomotion. Pharmacol Biochem Behav. 1990 Aug;36(4):735-8.
2	ClinicalTrials.gov (NCT00033657) Radiation Therapy and Chemotherapy Before and After Surgery in Treating Patients With Esophageal Cancer
3	ClinicalTrials.gov (NCT00057837) Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer